ASP Isotopes (NASDAQ:ASPI) CEO Robert Ainscow Sells 67,500 Shares of Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CEO Robert Ainscow sold 67,500 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $7.51, for a total transaction of $506,925.00. Following the transaction, the chief executive officer owned 1,579,693 shares of the company’s stock, valued at $11,863,494.43. This represents a 4.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Robert Ainscow also recently made the following trade(s):

• On Tuesday, October 14th, Robert Ainscow sold 22,500 shares of ASP Isotopes stock. The shares were sold at an average price of $13.60, for a total transaction of $306,000.00.
• On Monday, September 8th, Robert Ainscow sold 8,438 shares of ASP Isotopes stock. The stock was sold at an average price of $8.53, for a total value of $71,976.14.

ASP Isotopes Stock Performance

Shares of NASDAQ:ASPI opened at $7.70 on Thursday. The company has a debt-to-equity ratio of 3.53, a current ratio of 14.72 and a quick ratio of 14.56. ASP Isotopes Inc. has a 1 year low of $3.65 and a 1 year high of $14.49. The firm has a market capitalization of $719.05 million, a PE ratio of -6.09 and a beta of 3.28. The business’s 50 day moving average price is $9.60 and its 200-day moving average price is $8.79.

ASP Isotopes (NASDAQ:ASPI) last announced its earnings results on Wednesday, November 19th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.05). The business had revenue of $4.89 million for the quarter, compared to analyst estimates of $2.25 million. ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%. As a group, equities research analysts expect that ASP Isotopes Inc. will post -0.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on ASPI shares. Loop Capital set a $15.00 price target on ASP Isotopes in a report on Monday, October 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of ASP Isotopes in a research report on Thursday, October 30th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a research report on Wednesday, September 17th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, ASP Isotopes has a consensus rating of “Hold” and an average target price of $13.00.

Hedge Funds Weigh In On ASP Isotopes

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of ASP Isotopes by 37.9% during the third quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock worth $43,451,000 after purchasing an additional 1,241,024 shares in the last quarter. AWM Investment Company Inc. grew its stake in shares of ASP Isotopes by 6.2% in the first quarter. AWM Investment Company Inc. now owns 4,511,186 shares of the company’s stock worth $21,157,000 after acquiring an additional 265,000 shares in the last quarter. Philadelphia Financial Management of San Francisco LLC grew its stake in shares of ASP Isotopes by 11.2% in the first quarter. Philadelphia Financial Management of San Francisco LLC now owns 3,508,062 shares of the company’s stock worth $16,453,000 after acquiring an additional 354,517 shares in the last quarter. Rovida Investment Management Ltd increased its position in shares of ASP Isotopes by 45.5% during the third quarter. Rovida Investment Management Ltd now owns 3,200,000 shares of the company’s stock worth $30,688,000 after acquiring an additional 1,000,000 shares during the period. Finally, Rovida Advisors Inc. acquired a new stake in shares of ASP Isotopes in the second quarter valued at $16,148,000. Institutional investors and hedge funds own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.